Skip to main content
PMC home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 2003 Jun;12(3):167–171. doi: 10.1080/0962935031000134888

Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia.

Joanna Gora-Tybor 1, Jerzy Z Blonski 1, Tadeusz Robak 1
PMCID: PMC1781611  PMID: 12857600

Abstract

The serum concentration of two pro-angiogenic cytokines: basic fibroblast growth factor (bFGF) and transforming growth factor beta1 (TGF-beta1), and anti-angiogenic factor endostatin in the serum of 80 never treated B-cell chronic lymphocytic leukemia (CLL) patients and 27 healthy volunteers was measured using an enzyme linked immunosorbent assay. The serum levels of both bFGF and TGF-beta1 were found to be significantly higher in the CLL group (median 40.5 pg/ml and 38.6 ng/ml respectively) when compared to the control group (median 9.4 pg/ml and 18.9 ng/ml, respectively) (p<0.001). The levels of endostatin were not significantly different in CLL and control groups (median 12.3 ng/ml and 8.4 ng/ml, respectively) (p=0.09). In the group of CLL patients the level of bFGF was significantly higher in patients with progressive disease as compared with patients with stable disease (median 90.5 pg/ml and 40.5 pg/ml respectively) (p<0.001). Patients in Rai stage III and IV also had significantly higher levels of bFGF than patients in Rai stage 0-II (median 100.1 pg/ml and 29.3 pg/ml respectively) (p<0.001). The levels of both TGF-beta1 and endostatin were lower in patients in Rai stage III and IV (median 28.9 ng/ml and 9.1 ng/ml respectively) than in patients in Rai stage 0-II (42.8 ng/ml and 13.1 ng/ml respectively) (p<0.001 and p=0.002 respectively). The level of endostatin was also lower in the group of CLL patients with progressive disease (median 10.0 ng/ml) as compared to patients with stable disease (median 20.5 ng/ml) (p=0.008). In conclusion, the disturbance in the balance between pro- and anti-angiogenic factors may have an important influence on the course of CLL.

Full Text

The Full Text of this article is available as a PDF (92.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bertolini F., Mancuso P., Gobbi A., Pruneri G. The thin red line: angiogenesis in normal and malignant hematopoiesis. Exp Hematol. 2000 Sep;28(9):993–1000. doi: 10.1016/s0301-472x(00)00508-7. [DOI] [PubMed] [Google Scholar]
  2. Bertolini F., Paolucci M., Peccatori F., Cinieri S., Agazzi A., Ferrucci P. F., Cocorocchio E., Goldhirsch A., Martinelli G. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol. 1999 Aug;106(2):504–509. doi: 10.1046/j.1365-2141.1999.01547.x. [DOI] [PubMed] [Google Scholar]
  3. Chen H., Treweeke A. T., West D. C., Till K. J., Cawley J. C., Zuzel M., Toh C. H. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood. 2000 Nov 1;96(9):3181–3187. [PubMed] [Google Scholar]
  4. Cheson B. D., Bennett J. M., Grever M., Kay N., Keating M. J., O'Brien S., Rai K. R. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996 Jun 15;87(12):4990–4997. [PubMed] [Google Scholar]
  5. DeCoteau J. F., Knaus P. I., Yankelev H., Reis M. D., Lowsky R., Lodish H. F., Kadin M. E. Loss of functional cell surface transforming growth factor beta (TGF-beta) type 1 receptor correlates with insensitivity to TGF-beta in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 1997 May 27;94(11):5877–5881. doi: 10.1073/pnas.94.11.5877. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Douglas R. S., Capocasale R. J., Lamb R. J., Nowell P. C., Moore J. S. Chronic lymphocytic leukemia B cells are resistant to the apoptotic effects of transforming growth factor-beta. Blood. 1997 Feb 1;89(3):941–947. [PubMed] [Google Scholar]
  7. Duensing S., Atzpodien J. Increased intracellular and plasma levels of basic fibroblast growth factor in B-cell chronic lymphocytic leukemia. Blood. 1995 Apr 1;85(7):1978–1980. [PubMed] [Google Scholar]
  8. Feldman A. L., Pak H., Yang J. C., Alexander H. R., Jr, Libutti S. K. Serum endostatin levels are elevated in patients with soft tissue sarcoma. Cancer. 2001 Apr 15;91(8):1525–1529. doi: 10.1002/1097-0142(20010415)91:8<1525::aid-cncr1161>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  9. Feldman A. L., Tamarkin L., Paciotti G. F., Simpson B. W., Linehan W. M., Yang J. C., Fogler W. E., Turner E. M., Alexander H. R., Jr, Libutti S. K. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clin Cancer Res. 2000 Dec;6(12):4628–4634. [PubMed] [Google Scholar]
  10. Gora-Tybor J., Blonski J. Z., Robak T. Cladribine decreases the level of angiogenic factors in patients with chronic lymphocytic leukemia. Neoplasma. 2002;49(3):145–148. [PubMed] [Google Scholar]
  11. Hefler L., Tempfer C., Kainz C., Obermair A. Serum concentrations of endostatin in patients with vulvar cancer. Gynecol Oncol. 1999 Jul;74(1):151–152. doi: 10.1006/gyno.1999.5496. [DOI] [PubMed] [Google Scholar]
  12. Kay N. E., Bone N. D., Tschumper R. C., Howell K. H., Geyer S. M., Dewald G. W., Hanson C. A., Jelinek D. F. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia. 2002 May;16(5):911–919. doi: 10.1038/sj.leu.2402467. [DOI] [PubMed] [Google Scholar]
  13. Kay N. E., Jelinek D. F., Peterson L. Angiogenesis in B-chronic lymphocytic leukemia. Leuk Res. 2001 Aug;25(8):709–710. doi: 10.1016/s0145-2126(01)00002-9. [DOI] [PubMed] [Google Scholar]
  14. Kini A. R., Kay N. E., Peterson L. C. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia. 2000 Aug;14(8):1414–1418. doi: 10.1038/sj.leu.2401825. [DOI] [PubMed] [Google Scholar]
  15. Kremer J. P., Reisbach G., Nerl C., Dörmer P. B-cell chronic lymphocytic leukaemia cells express and release transforming growth factor-beta. Br J Haematol. 1992 Apr;80(4):480–487. doi: 10.1111/j.1365-2141.1992.tb04561.x. [DOI] [PubMed] [Google Scholar]
  16. Lagneaux L., Delforge A., Bron D., Massy M., Bernier M., Stryckmans P. Heterogenous response of B lymphocytes to transforming growth factor-beta in B-cell chronic lymphocytic leukaemia: correlation with the expression of TGF-beta receptors. Br J Haematol. 1997 Jun;97(3):612–620. doi: 10.1046/j.1365-2141.1997.792715.x. [DOI] [PubMed] [Google Scholar]
  17. Lagneaux L., Delforge A., Dorval C., Bron D., Stryckmans P. Excessive production of transforming growth factor-beta by bone marrow stromal cells in B-cell chronic lymphocytic leukemia inhibits growth of hematopoietic precursors and interleukin-6 production. Blood. 1993 Oct 15;82(8):2379–2385. [PubMed] [Google Scholar]
  18. Lotz M., Ranheim E., Kipps T. J. Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells. J Exp Med. 1994 Mar 1;179(3):999–1004. doi: 10.1084/jem.179.3.999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Menzel T., Rahman Z., Calleja E., White K., Wilson E. L., Wieder R., Gabrilove J. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. Blood. 1996 Feb 1;87(3):1056–1063. [PubMed] [Google Scholar]
  20. Molica S. Angiogenesis in B-cell chronic lymphocytic leukemia: methods of study, clinical significance and prognostic implications. Leuk Lymphoma. 2001 Aug;42(4):603–607. doi: 10.3109/10428190109099320. [DOI] [PubMed] [Google Scholar]
  21. Molica S., Vitelli G., Levato D., Ricciotti A., Digiesi G. Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia. Br J Cancer. 2002 Jan 7;86(1):31–35. doi: 10.1038/sj.bjc.6600022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Nagashima M., Asano G., Yoshino S. Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis. J Rheumatol. 2000 Oct;27(10):2339–2342. [PubMed] [Google Scholar]
  23. O'Reilly M. S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W. S., Flynn E., Birkhead J. R., Olsen B. R., Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997 Jan 24;88(2):277–285. doi: 10.1016/s0092-8674(00)81848-6. [DOI] [PubMed] [Google Scholar]
  24. Padró T., Ruiz S., Bieker R., Bürger H., Steins M., Kienast J., Büchner T., Berdel W. E., Mesters R. M. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 2000 Apr 15;95(8):2637–2644. [PubMed] [Google Scholar]
  25. Pepper M. S. Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev. 1997 Mar;8(1):21–43. doi: 10.1016/s1359-6101(96)00048-2. [DOI] [PubMed] [Google Scholar]
  26. Perez-Atayde A. R., Sallan S. E., Tedrow U., Connors S., Allred E., Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1997 Mar;150(3):815–821. [PMC free article] [PubMed] [Google Scholar]
  27. Pertovaara L., Kaipainen A., Mustonen T., Orpana A., Ferrara N., Saksela O., Alitalo K. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem. 1994 Mar 4;269(9):6271–6274. [PubMed] [Google Scholar]
  28. Poon R. T., Fan S. T., Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol. 2001 Feb 15;19(4):1207–1225. doi: 10.1200/JCO.2001.19.4.1207. [DOI] [PubMed] [Google Scholar]
  29. Rai K. R., Sawitsky A., Cronkite E. P., Chanana A. D., Levy R. N., Pasternack B. S. Clinical staging of chronic lymphocytic leukemia. Blood. 1975 Aug;46(2):219–234. [PubMed] [Google Scholar]
  30. Rajkumar S. V., Fonseca R., Witzig T. E., Gertz M. A., Greipp P. R. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia. 1999 Mar;13(3):469–472. doi: 10.1038/sj.leu.2401336. [DOI] [PubMed] [Google Scholar]
  31. Robak E., Woźniacka A., Sysa-Jedrzejowska A., Stepień H., Robak T. Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus. Lupus. 2002;11(6):348–355. doi: 10.1191/0961203302lu199oa. [DOI] [PubMed] [Google Scholar]
  32. Robak T., Bloński J. Z., Kasznicki M., Blasińska-Morawiec M., Krykowski E., Dmoszyńska A., Mrugala-Spiewak H., Skotnicki A. B., Nowak W., Konopka L. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood. 2000 Oct 15;96(8):2723–2729. [PubMed] [Google Scholar]
  33. Salven P., Teerenhovi L., Joensuu H. A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma. Blood. 1999 Nov 15;94(10):3334–3339. [PubMed] [Google Scholar]
  34. Schuler M., Tretter T., Schneller F., Huber C., Peschel C. Autocrine transforming growth factor-beta from chronic lymphocytic leukemia-B cells interferes with proliferative T cell signals. Immunobiology. 1999 Feb;200(1):128–139. doi: 10.1016/s0171-2985(99)80038-2. [DOI] [PubMed] [Google Scholar]
  35. Wunderlich H., Steiner T., Junker U., Knöfel B., Schlichter A., Schubert J. Serum transforming growth factor-beta1 in patients with renal cell carcinoma. J Urol. 1997 May;157(5):1602–1603. [PubMed] [Google Scholar]
  36. Xu J., Menezes J., Prasad U., Ahmad A. Elevated serum levels of transforming growth factor beta1 in Epstein-Barr virus-associated nasopharyngeal carcinoma patients. Int J Cancer. 1999 Aug 20;84(4):396–399. doi: 10.1002/(sici)1097-0215(19990820)84:4<396::aid-ijc11>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  37. Yamagata M., Shiratori Y., Dan Y., Shiina S., Takayama T., Makuuchi M., Omata M. Serum endostatin levels in patients with hepatocellular carcinoma. Ann Oncol. 2000 Jun;11(6):761–762. doi: 10.1023/a:1008318526938. [DOI] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES